A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

February 26, 2015
Daclatasvir and Sovaldi Cure 97% of Hep C in Those Coinfected With HIV
Twelve weeks daclatasvir and Sovaldi offered a hep C 97 percent cure rate among those with genotypes 1 through 4 who were coinfected with HIV.
Financial Incentives Largely Fail to Improve Care for People With HIV
A large-scale program offering HIV-positive people financial incentives to get into medical care and to maintain a fully suppressed virus has failed overall.
February 25, 2015
No Progress in Testing or Treating Africans Earlier in HIV Disease
The average CD4 count of HIV-positive sub-Saharan Africans upon diagnosis or starting treatment has not risen over the past decade, indicating an overall failure to detect and treat the virus earlier in the course of HIV disease.
Attachment Inhibitor from BMS, A New Class of HIV Drug, Shows Promise
Given to treatment-experienced people with HIV, the attachment inhibitor BMS-663068 demonstrated potentcy in the range of Norvir-boosted Reyataz.
Cancer Rate is 50 Percent Higher Among People With HIV
The cancer rate of Americans diagnosed with HIV is an estimated 50 percent greater than that of the HIV-negative population.
BMS Maturation Inhibitor Is Potent Against HIV in Early Trial
Bristol-Myers Squibb’s investigatory maturation inhibitor BMS-955176 showed promise in an early trial examining its potency against HIV.
February 24, 2015
Preventing HIV in One High-Risk Person Saves up to $340,000
Researchers have estimated that preventing HIV in one high-risk individual saves an estimated $229,800 to $338,500 in lifetime medical costs.
PrEP Reduces Group of Gay Men’s Risk of HIV By 86% in UK Study
A group of British gay and bi men given Truvada as PrEP had an overall 86 percent lower risk of HIV as a consequence.
Intercourse-Based PrEP Dosing Lowers HIV Risk in Gays, But Why?
A strategy of taking Truvada as PrEP only in the days surrounding intercourse reduced the overall risk of HIV by 86 percent among gay men. However, the ongoing study has thus far failed to determine whether the dosing protocol itself was responsible for the reduction in risk, as opposed to the fact that the study participants ultimately wound up taking Truvada with some level of regularity.
Anti-HIV Vaginal Gel Study Fails Because of Poor Adherence
A trial of a Viread (tenofovir)-containing vaginal gel to protect against HIV has failed because the South African women participants used it at such low rates.
February 23, 2015
91% of HIV Passes From Those Unaware They’re Infected or Not in Care
An estimated 91.5 percent of new HIV transmits from people who do not know they are infected or who are not in medical care for the virus.
98% Hep C Cure Rate For Harvoni in Those Coinfected With HIV
Twelve weeks of Harvoni yielded a 98 percent hepatitis C cure rate among those with genotype 1 of the virus who are coinfected with HIV.
High Hep Cure Rates for Viekira Pak Among Those Coinfected With HIV
Viekira Pak plus ribavirin boasts a hepatitis C cure rate in the low-90 percent range among those with genotype 1 of the virus who are coinfected with HIV.
Critiquing UNAIDS HIV Prevention Goals, AVAC Calls For Honed Strategy
The global HIV advocacy group AVAC has raised an alarm that global goals for HIV prevention may prove ineffectual due to their vagueness.
February 20, 2015
Anti-HIV Molecule May Lead to Vaccine and Long-Acting Treatment
A new molecule blocked a simian version of HIV from attaching to immune cells, and may work as both a long-acting treatment and a vaccine for HIV in humans.
February 19, 2015
PrEP Users’ Sexually Acquired Hep C Suggests Need for Routine Testing
Evidence of sexual acquisition of hepatitis C among gay men receiving PrEP at a San Francisco clinic has prompted a call for routine testing for the virus among PrEP users.
February 18, 2015
African-American HIV Conspiracy Theories Derive From Mistrust
African Americans who believe conspiracy theories that HIV was created by the government to kill off blacks are motivated by distrust of the government.
February 17, 2015
An Aggressive Form of HIV Appears to Have Surfaced in Cuba
Researchers believe they have found an aggressive strain of HIV among Cubans that progresses to AIDS in just three years, instead of the typical 10.
February 13, 2015
Daily Antibiotic May Work as PrEP Against STIs Other Than HIV
A daily dose of the antibiotic doxycycline may be effective as pre-exposure prophylaxis (PrEP) against gonorrhea, chlamydia and syphilis.
February 12, 2015
Kidneys From Donors With HIV Transplant Well Into HIV-Positive Recipients
People with HIV can successfully receive transplanted kidneys from HIV-positive donors.
February 11, 2015
HIV and Syphilis Smartphone Assay Would Aid Testing in Remote Areas
Researchers have developed a low-cost smartphone accessory that can conduct a 15-minute test for HIV and syphilis with only a finger prick.
February 10, 2015
Death Rates Among HIV-Positive People, Especially Blacks, Are Falling
The death rate of HIV-positive African Americans has declined considerably in recent years, although significant disparities still exist when the statistics are compared with those of whites and Latinos,
February 09, 2015
A Call for Improved HIV-Related Scientific Literacy on the Front Lines
Poor scientific literacy among non-medical members of the HIV-related workforce must be addressed in order to better fight the epidemic.
February 05, 2015
Failed VOICE PrEP Trial Failed to Preempt Lies About Adherence
The failure of the VOICE trial of oral and vaginal gel PrEP was the result of low adherence among the sub-Saharan African women participants, many of whom actively lied about their adherence.
February 04, 2015
New Guidelines for Bone Care Among People With HIV
An international panel has released new guidelines on the management of bone density decline among people with HIV.
February 03, 2015
Craigslist Personals’ Intro Into Local Markets Linked to 16% Rise in HIV
When Craigslist introduced its personal section into respective areas around the country, the arrival was linked to a 15.9 percent risk in HIV incidence.
February 02, 2015
Early HIV Treatment Advantage Is Lost If Treatment Is Interrupted
The immune recovery benefits conferred by starting antiretrovirals for HIV shortly after infection are lost if treatment is later interrupted.
HIV Viral Rebounds Predict Fibrosis in HCV-Coinfected People
People coinfected with HIV and hepatitis C are more likely to develop liver fibrosis if they experience an HIV viral load rebound, rather than just a blip.
Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?

February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006
October 2005

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.